Found 6 matching trials
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
PHASE3Evidence suggests that the addition of cetuximab or bevacizumab to doublet ...
Location
Zhongshan Hospital, Fudan University
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
PHASE3Multimodality treatment that comprises preoperative fluoropyrimidine with c...
Location
The Sixth Affiliated Hospital of Sun Yat-sen University
Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
PHASE2This is an open-label, parallel-group, phase 2 randomized trial which rando...
Location
Sixth Affiliated Hospital of Sun Yat-sen University
The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases
PHASE2This single-arm study will evaluate the resection rate of liver metastases ...
Location
National Cheng-Kung University Hospital
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
PHASE3The current clinical trials and data on the triplet regimen combined with b...
Status
Active Not Recruiting
Location
Gastrointestinal Hospital, Sun Yat-sen University
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
PHASE3Colorectal cancer patients with initially unresectable liver-only metastase...
Location
Zhongshan Hospital, Fudan University